

**MANAGEMENT OF FELINE DIABETES MELLITUS:  
PART 1. WHICH INSULIN DO I CHOOSE & HOW DO I ADJUST THE DOSE?**

**Jacquie Rand BVSc, DVSc, MACVS, Dip ACVIM; Rhett Marshall BVSc, MACVS**

Centre for Companion Animal Health, School of Veterinary Science, The University of Queensland, Brisbane  
Australia

**MANAGEMENT OF FELINE DIABETES**

Therapy for diabetes should be instituted as soon as possible after diagnosis. The main goal of therapy is to achieve euglycemia without the need for insulin therapy, commonly termed diabetic remission. For those cats not achieving remission the goals are to resolve clinical signs and avoid hypoglycemia. Administration of insulin and dietary modification are the principal therapies used for management of diabetic cats. Oral hypoglycemic drugs have limited usefulness in the initial management of diabetic cats, and if used as a sole agent without insulin, will substantially decrease the probability of remission.

Cats that are not substantially dehydrated and are still eating can be treated with subcutaneous insulin. Cats initially presented with diabetic ketoacidosis can be treated with subcutaneous insulin after stabilization. When used intramuscularly or intravenously, glargine acts like regular insulin and can be used instead of regular insulin for initial stabilization of diabetic cats. The use of long-acting insulins, particularly glargine and detemir, and low carbohydrate diets facilitates achieving better glycaemic control and increases the probability of remission, while minimizing the chance of hypoglycemia. If using lente insulin, because clinical hypoglycemia is more common and can be life-threatening, avoid aiming for perfect glycaemic control.

**Insulin therapy**

Long-acting insulin therapy remains the preferred initial and long-term treatment of choice for diabetes mellitus in cats. Its effectiveness and safety is enhanced when combined with a low carbohydrate diet. Oral hypoglycemic agents such as acarbose may be effective as an additional therapy in cats which require a high carbohydrate diet, provided they are not *ad libitum* feeding. Many types of insulin are available and have been used in cats. Achieving good glycaemic control with intermediate acting potent insulins such as NPH and lente is often difficult, and increases the risk of clinical hypoglycemia. Recent data suggests that the long-acting insulins glargine and detemir provide better glycaemic control and reduced risk of clinical hypoglycemia when given twice daily and combined with a low carbohydrate diet. More importantly, their use results in a significantly higher probability for remission.

**Oral hypoglycemic drugs**

The use of oral hypoglycemic drugs to treat feline diabetes has been limited for a number of reasons. Many owners find administering tablets more difficult than injecting with insulin. Drugs which stimulate insulin secretion (eg. sulphonylureas) require adequate beta cell function to be effective, and if there is inadequate glucose-lowering effect, persistent hyperglycemia can lead to continued beta cell loss through glucose and lipid toxicity. These drugs may also stimulate accelerated islet amyloid deposition exacerbating beta cell loss. However, newer GLP-1 analogues and agonists are an emerging class of drugs for use in feline diabetes. Acarbose acts by reducing glucose absorption from the gastrointestinal tract and is indicated as an adjunct to insulin therapy in cats which are meal fed a high carbohydrate diet. It is not beneficial in cats on a low carbohydrate diet, and feeding a low carbohydrate diet with approximately 6% of energy from carbohydrate has the same or greater effect in lowering postprandial glucose concentrations as feeding a high carbohydrate diet and administering acarbose. The greatest indication for using acarbose is in cats with advanced renal failure which require a restricted protein diet. However, these cats usually have a reduced appetite and need to be fed *ad libitum*, which greatly reduces the efficacy of acarbose.

**Monitoring therapeutic efficacy**

Response to treatment can be evaluated in a number of ways, and no individual modality should be used as the sole parameter for adjusting therapy. A combination of owner assessment, clinical signs, and changes in body weight and water intake are often the best indicators of glycaemic control. Dosage changes can be made based on a number of different blood glucose parameters, and optimally should include more than one parameter. The pre-insulin glucose concentration is important when using glargine, detemir and PZI, as there is often a persisting effect from the previous injection. Nadir (lowest) glucose concentration is important for dosage adjustment. It limits the dose increase that can be made when nadir glucose concentration is in the lower end of the normal reference range. Water drunk and urine glucose concentration are probably more important when using glargine than for other types of insulin, and is discussed below.

When using other insulins (eg lente or NPH), dosage changes are usually based on nadir blood glucose. Pre-insulin glucose, time to nadir and the time to return to baseline are also used where appropriate, and recommendations for their use are listed in table 2. Water drunk, urine glucose and clinical assessment may be less important for making dosage changes with lente and NPH insulins, but should still receive consideration when adjusting dosage.

Table 1: Parameters for changing insulin dosage and frequency based on blood glucose measurements when using lente or NPH insulin in diabetic cats.

Blood Glucose Variable	Recommendation
Use an initial dose 0.5 U/kg of lean body weight BID if blood glucose is $\geq 360$ mg/dL ( $> 20$ mmol/L) and 0.25 U/Kg BID if glucose $< 360$ mg/dL ( $> 20$ mmol/L).	
If pre-insulin blood glucose concentration is $< 210$ mg/dL ( $< 12$ mmol/L)	With-hold insulin and check for diabetic remission provided cat treated for a minimum of 2 weeks; otherwise reduce dose
If pre-insulin blood glucose concentration is 211-250mg/dL (13 - 16mmol/L)	Total dose should be no more than 1U/cat bid
If nadir blood glucose concentration is $< 54$ mg/dL ( $< 3$ mmol/L)	Dose should be reduced by 50 %
If nadir blood glucose concentration is 54-90mg/dL (3 – 5mmol/L)	Dose should be reduced by 1U if poor control of clinical signs of diabetes; dose should remain the same if exemplary control of clinical signs
If nadir blood glucose concentration is 91-180mg/dL(6 – 9mmol/L)	Dose should remain the same
If nadir blood glucose concentration is $> 180$ mg/dL( $> 10$ mmol/L)	Dose should be increased by 1U
If nadir blood glucose concentration occurs within 3 hours of insulin administration, or blood glucose returns to baseline within 8 hours	Change to longer acting insulin (ie. Glargine, detemir or PZI)
If the nadir blood glucose concentration occurs at 8 hours or later	Once daily administration may be used, although twice daily administration at a reduced dose is preferred

### Glargine and detemir

Glargine is a new human synthetic insulin analogue produced by recombinant DNA technology utilizing *E.Coli*. It differs from human insulin in that the amino acid asparagine at position A21 is replaced by glycine and two arginines are added to the B-chain terminus. Glargine is a clear aqueous solution in 100U/ml vials with pH=4 until injected subcutaneously. The interaction of the acidic insulin and the relatively neutral pH of the subcutaneous tissues forms micro-precipitates, and has a relatively constant systemic absorption profile. The formation of micro-precipitates and slow absorption are dependant on the acidity of glargine, hence glargine cannot be mixed or diluted.

Glargine is marketed for human patients as a very long-acting “peak less” insulin, with regard to its glucose lowering effects. It is designed to provide a basal or background insulin concentration, with the intention that a shorter-acting insulin be administered at meal times to achieve optimal glycemic control. Insulin glargine gained approval from the United States Food and Drug Administration in June 2000, for use in treating type 1 and type 2 diabetes in humans. The expected benefits in diabetic cats of an insulin preparation with a longer duration of action include improved glycemic control resulting in increased rates of diabetic remission, reduced rates of euthanasia, and decreased cost to clients.

The pharmacokinetics and pharmacodynamics of once daily administration of glargine compared with two of the most commonly used insulin preparations, porcine lente and protamine zinc insulin (PZI), has been reported in healthy cats. Once daily administration of glargine was found to have a similar mean daily glucose concentration and area under the 24hr glucose curve to PZI, and both were significantly lower than lente insulin. Glargine produced a glucose nadir later than PZI or lente, and had longer duration of action than lente. The duration of action for glargine was 22hrs, and 5 of the 9 cats had significantly decreased blood glucose concentration at 24hrs.

The administration of glargine once daily versus twice daily has been compared in healthy cats. A longer effect was achieved by administering glargine BID compared to once daily. Once daily administration of glargine has been shown to produce similar remission rates to twice daily dosing of lente insulin. Because excellent glycemic control facilitates remission and superior glycemic control is achieved if glargine is injected twice daily, twice daily dosing should be used for at least the first 4 months of treatment after diagnosis.

The usefulness of glargine for treating newly diagnosed diabetic cats has been evaluated. Twenty-four newly diagnosed diabetic cats (17m,7f) were treated with either glargine, PZI or lente (n=8 for each group) and fed a very low carbohydrate-high protein diet (Purina DM canned). Insulin was initially given at 0.5U/kg BID S/C if blood glucose was  $> 360$ mg/dl, and 0.25U/kg BID S/C if blood glucose was  $< 360$ mg/dl. Insulin dose was then adjusted based on serial blood glucose curves and water intake. Cats were defined as achieving diabetic remission if normoglycemia was maintained without insulin therapy for more than 2 weeks.

At diagnosis, there was no statistical difference between treatment groups for age, body weight, body condition score, or concentrations of fructosamine, blood glucose, B-hydroxybutyrate or bicarbonate.

There was a non-significant trend for glargine treated cats to have lower 12hr glucose concentrations after 10 and 17 days, than those treated with PZI or lente. Mean 12hr blood glucose at 4 weeks was significantly lower for glargine than PZI and lente treated cats. Fructosamine concentration after 4 weeks of treatment was significantly lower than at diagnosis for glargine treated cats but not for PZI or lente.

All 8 cats treated with glargine went into diabetic remission within 4 months of beginning treatment, while 3 cats treated with PZI and 2 cats treated with lente achieved diabetic remission.

Only 1 cat treated with glargine required an increase in insulin dose above 0.5U/kg BID, and 7 of 8 cats had their insulin dose reduced in the first 3 days of treatment. This is an important factor when initiating treatment with glargine, as there is usually a carry-over effect from the previous dose that may take several days to become apparent.

A significant finding in this trial was that no cat treated with glargine showed clinical hypoglycemia despite having biochemical hypoglycemia, while 2 cats treated with lente and 1 cat treated with PZI insulin exhibited signs of clinical hypoglycemia.

Glargine can be safely instituted at 0.5U/kg bid and serial blood glucose curves should be obtained daily for 3 days either in hospital or at home. When evaluating the blood glucose curve using glargine, it is often more useful to assess pre-insulin glucose concentration rather than the nadir glucose. We have found it often takes 3-5 days for a good glucose-lowering effect to be seen in the glucose curves, possibly because of the long duration of action and carry-over effect of glargine. Almost all cats will need to have their initial dose reduced within 2 weeks and many will achieve remission within 4 weeks.

Detemir is a newer synthetic insulin analogue with long duration of action that is produced using recombinant DNA technology in yeast (*Saccharomyces cerevisiae*). The insulin molecule is modified by the addition of an acylated fatty acid chain that enables reversible binding to plasma proteins, especially albumin, from where it is released slowly into plasma. This modification leads not only to a prolonged absorption from the subcutaneous tissue, but slow release from plasma proteins. Detemir results in similar remission rates and time to remission as glargine, but the median maximum dose used (1.75 IU/cat BID) is about 30% less than with glargine (2.5 IU/cat BID)

Monitoring and adjusting insulin dose when using glargine or detemir should be based on a number of parameters including; pre-insulin and nadir glucose concentration, water intake, urine glucose concentration and clinical assessment as shown in Table 2. We have found pre-insulin glucose concentrations measured at home an excellent tool for well-educated owners to safely modify daily doses of glargine or detemir. Cats treated with glargine should have a negative, 1+ or 2+ urine glucose (scale 0-4+) and a value of 3+ or 4+ likely indicates that a dose increase is required.

The good glycaemic control achieved when using glargine or detemir likely reverses glucose toxicity of the B-cells, which facilitates endogenous insulin production and a reduced requirement for exogenous administration. Insulin dose may be reduced sequentially as indicated by blood glucose concentration, urine glucose and water intake until the dose is ½-1U/cat SID. Even if normoglycemic, it is recommended that insulin is not withdrawn within 2 weeks of commencement of therapy. Sequential deduction of insulin dose to ½-1 U/cat SID is recommended before insulin is withdrawn, and the cat carefully monitored afterwards to ensure remission has continued. It is also imperative that cats remain on a low-carbohydrate diet with calorie control to prolong the remission period. Newly diagnosed diabetic cats that have good glycaemic control within the first few weeks of therapy, are very likely to go into diabetic remission. Cats that have been long-term diabetics are less likely to go into remission probably because of progressive B-cell loss associated with glucose toxicity. Remission rates are very significantly reduced if good glycaemic control is instituted longer than 6 months after diagnosis.

In conclusion, glargine and detemir are safe and effective in treating feline diabetes and are the preferred insulins in newly diagnosed diabetic cats. Long-term diabetic cats should be changed to glargine or detemir if there is poor glycaemic control or owners wish to pursue once daily injections. High remission rates are expected in newly diagnosed cats when combined with a low-carbohydrate diet and twice daily injections.

Table 2. Parameters for changing insulin dosage when using insulin glargine or detemir in diabetic cats and monitoring once a week in the initial stabilization phase.

Parameter used for dosage adjustment	Change in dose
Begin with 0.5 U/kg if blood glucose ( $\geq 360$ mg/dL ( $\geq 20$ mmol/L) or 0.25/kg of <u>ideal weight</u> if blood glucose is lower. Do not increase in first week unless minimum response to insulin occurs, but decrease if necessary. Monitor response to therapy for first 3 days If no monitoring is occurring in first week, begin with 1 U/cat BID	
If pre-insulin blood glucose concentration $>216$ mg/dL ( $>12$ mmol/L) <b>or</b> If nadir blood glucose concentration $>180$ mg/dL ( $>10$ mmol/L)	Increase by 0.25-1U depending on how high glucose is and dose of insulin
If pre-insulin blood glucose concentration $180 < 216$ mg/dL ( $\geq 10 - \leq 12$ mmol/L) and provided nadir is not in hypoglycemic range <b>or</b> Nadir blood glucose concentration is 90-160mg/dL (5-9mmol/L)	Same dose
If nadir glucose concentration is 54-72 mg/dL (3-4 mmol/L).	Use nadir glucose, water drunk, urine glucose and next pre-insulin glucose concentration to determine if insulin dose is decreased or maintained.
If pre-insulin blood glucose concentration $<180$ mg/dL ( $<10$ mmol/l)	Reduce by 0.5- 1UU <b>or</b> if total dose is 0.5U SID, stop insulin

<i>or</i>	and check for diabetic remission
If nadir blood glucose concentration < 54mg/dL (<3 mmol/l)	
If clinical signs of hypoglycemia are observed	Reduce by 50%
If blood glucose measurements are not available:	
If water intake is $\leq$ 20mls/kg on wet food or $\leq$ 60mls/kg on dry food	Same dose
If water intake is >20mls/kg on wet food or >60mls/kg on dry food	Increase dose by 0.5-1U
If urine glucose is > 3+ (scale 0 - 4+)	Increase dose by 0.5-1U
If urine glucose is negative	Decrease dose until 0.5-1 U SID and then check for diabetic remission

KEYWORDS, feline diabetes, diabetic remission, insulin, glargine

**Suggested reading:**

Selected articles are available our website: [www.uq.edu.au/vetschool/centrecat](http://www.uq.edu.au/vetschool/centrecat)

Rand JS and Marshall RD Diabetes mellitus in cats. Vet Clin North Am Small Anim Pract 35[1]:211-24 2005